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Purpose: To describe in detail a dataset consisting of serial four-dimensional com-
puted tomography (4DCT) and 4D cone beam CT (4DCBCT) images acquired dur-15
ing chemoradiotherapy of 20 locally-advanced, non-small cell lung cancer patients we
have collected at our institution and shared publicly with the research community.
Acquisition and Validation Methods: As part of an NCI-sponsored research
study 82 4DCT and 507 4DCBCT images were acquired in a population of 20 locally-
advanced non-small cell lung cancer patients undergoing radiation therapy. All sub-20
jects underwent concurrent radiochemotherapy to a total dose of 59.4-70.2 Gy using
daily 1.8 or 2 Gy fractions. Audio-visual biofeedback was used to minimize breath-
ing irregularity during all fractions, including acquisition of all 4DCT and 4DCBCT
acquisitions in all subjects. Target, organs at risk, and implanted ducial markers
were delineated by a physician in the 4DCT images. Image coordinate system origins25
between 4DCT and 4DCBCT were manipulated in such a way that the images can
be used to simulate initial patient setup in the treatment position. 4DCT images
were acquired on a 16-slice helical CT simulator with 10 breathing phases and 3 mm
slice thickness during simulation. In 13 of the 20 subjects, 4DCTs were also acquired
on the same scanner weekly during therapy. Daily 4DCBCT images were acquired30
on a commercial onboard CBCT scanner. An optically tracked external surrogate
was synchronized with CBCT acquisition so that each each CBCT projection was
time stamped with the surrogate respiratory signal through in-house software and
hardware tools. Approximately 2500 projections were acquired over a period of 8-10
minutes in half-fan mode with the half bow-tie lter. Using the external surrogate,35
the CBCT projections were sorted into 10 breathing phases and reconstructed with
an in-house FDK reconstruction algorithm. Errors in respiration sorting, reconstruc-
tion, and acquisition were carefully identied and corrected.
Data Format and Usage Notes: 4DCT and 4DCBCT images are avail-
able in DICOM format and structures through DICOM-RT RTSTRUCT40
format. All data are stored in the Cancer Imaging Archive (TCIA,
http://www.cancerimagingarchive.net/) as collection 4D-Lung and are publicly
available.
Discussion: Due to high temporal frequency sampling, redundant (4DCT and
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4DCBCT) data at similar timepoints, over-sampled 4DCBCT, and ducial mark-45
ers, this dataset can support studies in image-guided and image-guided adaptive
radiotherapy, assessment of 4D voxel trajectory variability, and development and
validation of new tools for image registration and motion management.
a)Electronic mail: gdhugo@vcu.edu
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I. INTRODUCTION
The prevalence of imaging in modern radiation therapy has enabled an improved under-50
standing of geometric variation of the patient anatomy during the treatment course. The
resulting widespread development of innovative methods to manage this variation during the
treatment course is broadly known as image-guided radiation therapy (IGRT). In-room and
onboard CT imaging supports characterization of patient anatomy in the treatment position
prior to each fraction, enabling improved radiation targeting accuracy1,2, evaluation of the55
validity of the initial treatment plan3, and assessing response to therapy4,5. Oine IGRT,
such as resimulation of the patient, can be used to modify the treatment plan directly6 or
integrate mid-treatment multimodality imaging such as positron emission tomography and
magnetic resonance imaging into this replanning process7,8. However, a variety of treatment-
site specic issues require careful design of the IGRT process to eciently and eectively60
manage geometric variation. For example, breathing motion during imaging and delivery
must be managed for thoracic and upper abdominal sites. Furthermore, anatomical varia-
tion is highly variable across patients, so a strategy that works for a single patient or clinic
may not be appropriate for another. Testing of new IGRT strategies and tools can therefore
be challenging, as it is often unknown what the best frequency and approach might be for65
the patient population without prospective evaluation in the clinic.
Fortunately, IGRT strategies and tools can often be thoroughly tested retrospectively
using a database of patient images through a strategy such as a virtual clinical trial6,9.
IGRT interventions, such as replans, couch shifts, etc. that don't actively impact the patient
geometry can be tested through such means. However, although there are numerous such70
published works, there is little publicly available data for conducting IGRT virtual clinical
trials. Data that is available tends to be of low temporal frequency sampling (e.g., once or
twice during the treatment course) or at inconsistent intervals from patient to patient.
The issue of lack of data is particularly critical in studies of IGRT in lung cancer. Because
of the issues of breathing-induced tissue motion, four dimensional (4D) imaging such as 4D75
fan beam CT (4DCT) and 4D cone beam CT (4DCBCT) are often required to appropriately
characterize motion. These datasets, being larger in size and requiring typically higher
imaging doses, are less frequently available.
The purpose of this work is to describe in detail a high-frequency 4DCT and 4D cone
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beam CT (4D CBCT) dataset of 20 lung cancer patients we have collected at our institution80
and shared publicly with the research community. This dataset has previously been used
by us for a variety of IGRT-related studies, including virtual clinical trials of adaptive
radiotherapy6, testing of deformable image registration10, a variety of studies describing
inter- and intrafraction variation of targets and normal tissue11{14, and testing of 4DCBCT-
based lung ventilation imaging15.85
II. ACQUISITION AND VALIDATION METHODS
A. Overview of Dataset
Throughout this work, we use the following terminology. An image refers to the complete
reconstructed 4D scan, whereas a phase refers to a single 3D frame in this 4D image. A
phase is therefore a 3D CT image, and a 4D image is thus composed of several (usually90
ten for our dataset) individual phases. In DICOM terminology (see Section III), an image
corresponds to a study and a phase to a series based on the way these data are stored in
this dataset.
The dataset consists of serial 4DCT and 4DCBCT images of 20 locally-advanced non-
small cell lung cancer patients undergoing radiochemotherapy at the VCU Massey Cancer95
Center in the Department of Radiation Oncology, from 2008 through 2012. All patients pro-
vided informed consent and were enrolled on an IRB-approved, NCI-sponsored prospective
imaging study. The subjects were imaged at or near the time of simulation with 4DCT.
Onboard 4DCBCT images were acquired on all subjects for most treated fractions (average
25, range 2 to 35 per patient). Thirteen of the 20 subjects also underwent repeat 4DCT100
imaging once or more during treatment (average 6, range 3 to 8 per patient). Figure 1 shows
example 4DCT and 4DCBCT phase images for two subjects. Targets and risk structures
were delineated by a physician on 4DCT images. See Table I for detailed image counts for
each subject.
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FIG. 1. Example images from the dataset. Top row, left to right: 4DCT, 4DCBCT at rst fraction,
4DCBCT at end of treatment for P104. Bottom row, corresponding images for P114. All images
from the end of inhalation breathing phase. The gross tumor volume outline is shown on 4DCT
for both patients. For P104, an implanted ducial marker is also outlined.
B. Acquisition105
1. Clinical parameters
Table II lists clinical treatment information for all subjects, including prescription and
fractionation, stage, tumor location and size. All patients underwent curative intent ra-
diochemotherapy to a total dose of 59.4-70.2 Gy using daily 1.8 or 2 Gy fractions. Because
the imaging dose was signicantly higher than typical for a clinical course (approximately110
4-5% of the prescription dose), imaging dose was estimated for each subject during planning
and included in the treatment plan for physician assessment and approval.
2. 4DCT
4DCT images were acquired on a 16-slice helical CT simulator (Brilliance Big Bore,
Philips Medical Systems, Andover, MA) as respiration-correlated CTs. An external respi-115
ration signal (Real-time Position Management (RPM), Varian Medical Systems, Inc.) was
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used to acquire the respiratory signal and to sort the raw data into 10 breathing phases (0%
to 90%) using a phase sorting approach. The 0% phase corresponds to end of inhalation.
The reconstructed slice thickness was 3 mm for all images and in-plane spacing was 0.98 to
1.17 mm. The technique was 120 kVp for all scans, 50 to 114 mA, and 3.53 to 5.83 ms.120
Audio-visual biofeedback was performed during all 4DCT acquisitions in all subjects
using a prototype system16. A training RPM waveform was acquired during the rst 4DCT
acquisition, and used as the reference waveform for guidance during all subsequent imaging
sessions.
The 4DCT images are stored with numerical identiers (series description, see Section III125
for details) in the form SXXX, where XXX is a number starting at 300. Note that this
identier does not necessarily correspond with the study (acquisition) date and therefore
images should not be ordered by series identier to simulate treatment order. Instead, the
study date should be used to order images. The study dates have been changed from the
actual acquisition dates to protect patient condentiality by adding a xed oset to the130
acquisition date of each scan. Modication was done in this manner to preserve the relative
time between acquisitions.
All subjects had a 4DCT acquired either as the clinical planning image, or near the
time of simulation. Four subjects were planned using free-breathing CT prior to the study
4DCT being acquired. For these four subjects, a study 4DCT was selected as a reference135
image, which we term the planning 4DCT. For these four subjects, Table III notes the time
from simulation until acquisition of this study planning 4DCT. Either way, the planning
image does not necessarily have a numerical identier of S300, due to either scan acquisition
issues or other factors. Table III lists the numerical identier for the image considered as
the planning CT for study purposes and provides the time from image acquisition until140
treatment start.
For subjects with repeat 4DCT during treatment, these 4DCT images were registered
to the planning 4DCT based on bony anatomy in the treatment planning system (Philips
Pinnacle v9.0). Supplemental material17 includes a table which lists the cumulative dose
delivered through the acquisition date for each of these repeat during-treatment 4DCT145
images.
As all 4DCT images were acquired on the same scanner, a Hounseld unit to electron
density calibration curve reproduced from the clinical treatment planning system is listed
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in Table IV to facilitate treatment planning on these images.
3. 4DCBCT150
4D-CBCT images were acquired on a commercial CBCT scanner (On-Board Imager v1.3,
Varian Medical Systems, Inc.) after in-house modication. The same external breathing
surrogate used for 4DCT was integrated into the CBCT acquisition system to stamp each
CBCT projection with the surrogate respiratory signal through in-house software and hard-
ware tools. Approximately 2000-2500 projections were acquired over a period of 8-10 minutes155
in half-fan mode with half bow-tie lter. The technique was 125 kVp, 20 mA, and 20 ms
in a single 360 slow gantry arc. The rotational gantry speed was varied using the technique
described by Lu et al.18 so that the angular sampling frequency was similar for each subject
and independent of breathing period. Using the external surrogate, the CBCT projections
were sorted into 10 breathing phases (0% to 90%, phase-based binning). As with 4DCT,160
the 0% phase corresponded with end of inhalation. 4DCBCT was reconstructed using an in-
house Feldkamp-Davis-Kress (FDK) reconstruction algorithm, with minimal preprocessing
(median ltering for noise reduction). Similar to 4DCT acquisition, audio-visual biofeedback
was performed during all 4DCBCT acquisitions. Figure 2 shows several phase images from
two 4DCBCT images acquired during the rst and last fractions for a single subject.165
The 4DCBCT image headers were generated so that aligning the planning 4DCT to the
4DCBCT by the origin in the image header will simulate the actual patient setup prior to
CBCT imaging.
Analogous to the 4DCT images, the numerical identier in the series description is for-
matted SXXX ; however, XXX for 4DCBCT images starts at 100. For similar reasons as170
for the 4DCT images, study date rather than numerical identier should be used to order
the images by acquisition time. Supplemental material17 includes a table which lists the
delivered cumulative dose through the date of acquisition for each 4DCBCT image. For
example, for the image acquired at the second fraction for a 2 Gy dose per fraction, this
table would list 4 Gy as the delivered cumulative dose for this image. The table is organized175
by study identier and subject number. Note that several subjects have multiple 4DCBCTs
acquired on the same day, which are pre- and post-treatment images. The order of these
two images can be found through the DICOM acquisition time tag.
8
FIG. 2. Example 4DCBCT phase images from the dataset, subject P105. Top row: First fraction
4DCBCT. Bottom row: 4DCBCT during 32nd fraction. The green dotted line shows the superior
tumor border at end of inhalation. The amplitude of motion is higher in the later 4DCBCT, as
evidenced by a more superior position and end of exhalation. Left to right, approximate breathing
phase: EI - End inhalation phase, MI - Mid inhalation phase, EE - End exhalation phase, ME - Mid
exhalation phase, EI. These correspond to the 0%, 20%, 40%, 60%, and 80% phases, respectively.
4. Fiducial marker description and implantation procedure
Seven of the patients had two to four 0.35 mm diameter (either 10 or 20 mm length) gold180
ducial markers (Visicoil, IBA Dosimetry, Bartlett, TN) implanted in or near the tumor
or involved lymph nodes. The markers were implanted prior to 4DCT imaging by a pul-
monologist using either endobronchial ultrasound-guided bronchoscopy or electromagnetic
navigational bronchoscopy (Covidien superDimension, Minneapolis, MN), with the patient
under conscious sedation. 4DCT images were then acquired on the same day. Details about185
marker location, stability, and analysis of marker to target variation can be found in Roman
et al.11
TABLE V: Count of target, organ at risk, and other struc-
tures delineated on the 4DCT images. A count of 10 means
all 10 phases of the 4DCT are delineated. A count of 1
means only the 0% phase has been delineated. (LN=Lymph
Node, Esoph=Esophagus, LL=Left Lung, RL=Right Lung,
Trach=Trachea, Vert=Vertebral Body)
Subject Image Targets Markers Organs at Risk Total
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Tumor LN LN2 A B C D Carina Cord Esoph Heart LL RL Trach Vert
100 S300 10 10 10 10 10 10 10 10 10 10 10 10 1 121
101 S300 10 10 10 10 10 10 10 10 10 10 10 10 1 121
102 S300 10 10 10 10 10 10 10 10 10 10 10 10 1 121
103 S301 10 10 10 10 10 10 10 10 10 10 1 101
104 S300 10 10 10 10 1 1 1 1 1 1 46
105 S300 10 10 10 10 1 1 1 1 1 10 55
106 S301 10 10 10 10 10 1 1 1 1 1 10 65
107 S300 10 10 10 1 10 1 10 10 10 72
107 S301 10 10 10 10 10 10 10 70
107 S302 10 10 10 10 1 1 10 52
107 S303 10 10 10 10 1 1 10 52
107 S304 10 10 10 10 10 10 10 70
108 S301 10 10 10 10 40
108 S302 10 10 10 10 40
108 S303 10 10 10 10 40
108 S304 10 10 10 1 1 1 1 1 10 45
108 S305 10 10 10 10 40
109 S300 10 10 10 30
109 S301 10 10 10 30
109 S302 10 10 1 1 1 1 1 10 35
109 S304 10 10 10 30
109 S305 10 10 10 30
110 S300 10 10 10 1 1 1 1 1 10 45
110 S301 10 10 10 10 40
110 S303 10 10 10 10 40
110 S305 10 10 10 10 40
110 S306 10 10 10 10 40
111 S301 10 10 10 10 1 1 1 1 1 10 55
111 S302 10 10 10 10 10 50
111 S303 10 10 10 10 40
111 S304 10 10 10 10 10 50
112 S301 10 10 10 1 1 1 1 1 10 45
112 S302 10 10 10 10 40
112 S303 10 10 10 10 40
112 S304 10 10 10 10 40
112 S305 10 10 10 10 40
112 S306 10 10 10 10 40
113 S300 10 10 10 10 40
113 S301 10 10 10 10 40
113 S302 10 10 10 10 40
113 S303 10 10 10 10 40
113 S304 10 10 10 10 40
114 S300 10 10 10 1 1 1 1 1 10 45
114 S301 10 10 10 10 40
114 S302 10 10 10 10 40
114 S303 10 10 10 10 40
114 S304 10 10 10 10 40
115 S300 10 10 10 10 1 1 1 1 10 54
115 S301 10 10 10 10 10 50
115 S302 10 10 10 10 10 50
115 S303 10 10 10 10 10 50
115 S304 10 10 10 10 10 50
115 S305 10 10 10 10 10 50
116 S300 10 10 10 10 10 50
116 S301 10 10 10 10 1 1 1 1 1 10 55
116 S302 10 10 10 10 10 50
116 S303 10 10 10 10 10 50
116 S304 10 10 10 10 10 50
117 S300 10 10 10 10 40
117 S301 10 10 10 10 40
117 S302 10 10 10 10 40
117 S303 10 10 10 10 40
117 S304 10 10 10 10 40
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117 S305 10 10 10 10 40
117 S306 10 10 10 10 40
117 S308 10 10 10 10 40
118 S302 10 10 10 10 40
118 S303 10 10 10 10 40
118 S304 10 10 10 10 40
118 S306 10 10 10 10 40
118 S307 10 10 10 10 40
118 S308 10 10 10 10 40
119 S300 10 10 10 10 10 50
119 S301 10 10 10 10 10 50
119 S302 10 10 10 10 10 50
119 S303 10 10 10 10 10 50
119 S304 10 10 10 10 10 50
119 S305 10 10 10 10 10 50
119 S306 10 10 10 10 10 50
119 S307 10 10 10 10 10 50
Grand Total 800 720 220 70 70 40 10 800 51 101 52 83 83 20 755 3875
5. Physician-delineated planning structures
A single experienced radiation oncologist (EW) supervised delineation of all target and
organ at risk (OAR) structures in the 4DCT datasets. The gross tumor volume and any190
visible involved lymph nodes were delineated on all phases of all 4DCT images. However,
because of the very large size of the dataset, organs at risk were contoured on only a subset
of images. Table V lists the number of delineated phases on each 4DCT, for each image and
structure. The delineated targets and organs at risk are named as listed in Table V with
` cXX' appended, where `XX' is the 4DCT phase from 00 to 90. For example, the tumor on195
the 40% phase is named `Tumor c40'.
For the seven patients with implanted ducial markers, these are labeled as markers A-D,
and also are listed in Table V. Markers, where visible, were delineated on 4DCT.
C. Validation
1. Processing and quality assurance200
After acquisition, 4DCT images were immediately reviewed for phase sorting artifact. If
present, the end inhalation tags placed by the Philips CT simulator were manually reviewed
and modied, if necessary. The image was again reconstructed and reviewed. Due to the
high volume of imaging, if this process did not correct artifact we did not reacquire 4DCT,
but instead accepted this image.205
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4DCBCT data in the form of raw projections and external surrogate signal were reviewed
after acquisition by physics personnel (SB, GH) for delity. Several issues were identied
and corrected when possible. The RPM system automatically identies breathing phase.
In 52 acquisitions (10 dierent patients) out of 507, the system incorrectly identied the
phase in at least a portion of the respiratory trace. These errors were corrected manually,210
and the 4DCBCT images were reconstructed using the corrected phase tags. Projection
angle errors were identied and corrected in 5 scans by plotting the projection angle vs.
projection number and locating projections that had substantial errors relative to adjacent
projections. Incomplete projections were identied in 4 scans which could not be corrected.
These images were removed from the dataset. After all error correction, each reconstructed215
4DCBCT image was reviewed visually.
Subject P113 had metal hardware implanted in the spine which generated artifact on
4DCBCT that was determined to limit use of these images. Because of this issue, 4DCBCT
imaging was discontinued in this subject after two fractions at start of treatment. However,
the subject remained on study for the 4DCT portion.220
All 4DCT and 4DCBCT data were then transferred to a research database. 4DCT were
initially reconstructed on the clinical CT simulator, deidentied and anonymized, and then
moved in DICOM format to the research database. For 4DCBCT data, raw projection
and RPM data were deidentied and anonymized and then moved to the research database
and reconstructed in DICOM format. The reconstructed 4DCBCT were then moved to the225
research database. A Pinnacle database was then constructed for each patient to enable
contouring.
A data acquisition and processing log was kept by study personnel for each subject so
that data integrity could be veried in the Pinnacle database against the log of acquired
data. A changelog of all data (unprocessed and processed) was kept for both images and230
structures. Out of 590 acquired images, one 4DCT image was unable to be transferred into
the database, leaving 589 images for processing and analysis.
The shifts applied to the 4DCT image origin (see Section II B 3) were veried by reg-
istering each 4DCBCT image to the planning 4DCT image and comparing the resulting
measured shift to the clinically-applied shift stored in the clinical record and verify system.235
Delineated structures were delineated by several physicians, but reviewed by a single
radiation oncologist (EW). To reduce intra-observer variation, each structure was initially
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delineated manually on a single phase image but then copied to other phases through rigid
registration for subsequent phases in the same image. The structure was then adjusted
manually to conform to the appropriate phase image.240
2. Known issues and limitations
There are several known issues and limitations of this dataset, based on the large size
and required high frequency of imaging.
First, sorting artifact is prevalent in the 4DCT images. While this makes some analyses
challenging, it does reproduce the clinical situation where such artifact is widespread19. Due245
to the already-high imaging dose from the study, we chose not to reacquire 4DCT images
for study purposes even if artifact was identied.
Second, 4DCBCT, not being commercially-available on our treatment units, was acquired
in a non-commercial mode. Thus, 4DCBCT image quality may not be of clinical quality due
to the use of in-house reconstruction with only minimal processing. Furthermore, despite250
the high angular sampling rate, reconstruction of 10 phases resulted in approximately 250
projections per phase. Thus, the 4DCBCT phase images all have noticeable view-aliasing
streak artifacts due to angular undersampling which limits signal to noise ratio and low
contrast detectability. Due to this limited image quality in 4DCBCT images, normal tissue
structures were not delineated in these images. Tumor and markers were delineated in255
4DCBCT11, but are not included in the current dataset. We are planning to process these
for eventual inclusion in the TCIA dataset.
III. DATA FORMAT AND USAGE NOTES
The Cancer Imaging Archive (TCIA) at the National Institutes of Health was selected as
the repository for long term storage of this dataset20. All data were exported from Pinnacle260
in DICOM (images) and DICOM-RT (structures) format. Although the dataset was initially
deidentied and anonymized at VCU, subsequently TCIA processed the dataset further to
ensure all potentially condential data were removed21.
Imaging data are stored with an anonymized patient name and identier. Subjects are
labeled as PXXX, where XXX is the subject from 100 to 119. The PatientID DICOM265
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tag is similarly labeled. Images can be identied by the DICOM study date tag, which as
mentioned was oset but preserves relative time between images. Also, the DICOM series
description contains the patient ID, study ID, and 4D phase. This tag is structured, for
example, as P4^P100^S102^I0, Gated, 40.0%. P4 identies an internal project identier at
VCU. P100 identies the subject as 100. S102 identies the study as study 102. Because270
the study identier is in the 100s, it is a 4DCBCT image (300 and up are reserved for 4DCT,
see Section II B 2). I0 is an internal identier that can be ignored. Finally, the phase is
identied as a percentage [0, 90]. DICOM tags related to acquisition such as the technique,
image orientation, and spacing were preserved during deidentication and anonymization.
When downloaded, at the time of publication the TCIA software stores the images on275
the user's system in a directory hierarchy rst by subject then by series UID. This directory
structure is dependent on the TCIA software, and may change in the future. To reorganize
the dataset on disk, it is best to use software that can parse the entire directory structure and
select DICOM les by the series description and other identiers described in the previous
paragraph. Many commercial image analysis software packages have such functionality. A280
free alternative is DicomBrowser (http://nrg.wustl.edu/software/dicom-browser).
The dataset can be found as collection 4D-Lung at the TCIA website
http://www.cancerimagingarchive.net/. Alternatively, the dataset can be accessed by
digital object identier (DOI) http://doi.org/10.7937/K9/TCIA.2016.ELN8YGLE.
The total size of the dataset is 183 GB, with 6690 individual DICOM les consisting of285
5890 image les and 800 RTSTRUCT les. DICOM and DICOM-RT compatibility have
been tested with Philips Pinnacle and MIM Maestro (MIM Software, Cleveland, OH).
IV. DISCUSSION
In spite of the limitations, this dataset has several advantages over similar datasets. First,
4DCBCT is available in a large number of treated fractions in many of the subjects. The290
4DCBCT images themselves are acquired with very ne angular sampling, consisting of
roughly 2000-2500 projections and being acquired over 8-10 minutes compared to approx-
imately 700 projections and 2 minutes for a typical clinical scan. The 4DCBCT therefore
have less view-aliasing (streaking) artifact than comparable clinical 4DCBCT scans. These
factors would allow the dataset to be of value for testing motion management strategies,295
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particularly the eect of inter-fraction changes on motion management.
Second, in many patients there are 4DCT images acquired on or near the same day as
4DCBCT images. This allows the high-quality 4DCT data to be used to validate strategies
and tools applied on the 4DCBCT images. For example, tools to improve CBCT to CT reg-
istration and localization22 could be tested in 4DCBCT but validated in 4DCT. Stability of300
image features and consistency of these features between CT and CBCT could be compared
to assess performance of radiomics strategies.
Third, ducial markers were implanted in seven subjects, were delineated in the 4DCT
images for these patients, and are visible in the 4DCBCT images. Such markers can be used
to validate a variety of studies, including image registration and tumor tracking, as well305
as evaluation of the delity of the markers as ducials themselves11. In separate work, we
segmented the markers in some of the CBCT projections, and reconstructed the 3D marker
positions during CBCT acquisition23. These data can be used to measure instantaneous
translation and rotation of lung tumors14, for example. Although not included in the TCIA
dataset, these data (both projections and marker traces) can be obtained by contacting the310
authors.
Finally, due to the high frequency of imaging, this dataset may be most useful for testing
of IGRT strategies such as online or oine correction protocols and for simulating adaptive
radiotherapy and related tools such as deformable image registration and dose mapping.
V. CONCLUSIONS315
In summary, we have constructed a dataset consisting of serial 4DCT and 4DCBCT
images acquired during chemoradiotherapy of 20 locally-advanced, non-small cell lung cancer
patients and corresponding delineated targets and organs at risk on a subset of these images.
The dataset has been archived in a standardized format in the publicly-available TCIA.
This dataset was used to test a variety of image-guided, adaptive, and motion management320
strategies for radiotherapy and should be of use to the research community for related
studies.
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TABLE I. Number and type of 4D images available in the VCU 4D Lung dataset. Each of
the 4DCT and 4DCBCT images is composed of 10 phase images.
Subject Number of 4DCT images (delineated) Number of 4DCBCT images Total images
100 1 (1) 33 34
101 1 (1) 10 11
102 1 (1) 16 17
103 3 (1)* 35 38
104 1 (1) 31 32
105 1 (1) 33 34
106 1 (1) 31 32
107 5 (5) 19 24
108 5 (5) 23 28
109 5 (5) 28 33
110 5 (5) 29 34
111 4 (4) 30 34
112 6 (6) 34 40
113 5 (5) 2 7
114 5 (5) 28 33
115 6 (6) 28 34
116 5 (5) 28 33
117 8 (8) 26 34
118 6 (6) 25 31
119 8 (8) 18 26
Total 82 (80) 507 589
*Subject 103 had an initial 4DCT for planning prior to marker implantation, and a
resimulation mid-treatment. These scans are included in the database but were not
delineated.
19
TABLE II. Clinical and treatment information for each subject. (RUL=right upper lung,
RLL=right lower lung, LUL=left upper lung, LLL=left lower lobe)
Subject T N M Overall stage Location Total dose (Gy) Number of fractions Dose per fraction (Gy) Tumor volume (cc)
100 4 3 0 IIIB RUL 62.6 32 2.0 (1.8 for 7) 75
101 4 3 0 IIIB RUL 66.6 37 1.8 27
102 4 2 0 IIIB LUL 66 33 2 171
103 4 2 0 IIIB RUL 66.6 37 1.8 58
104 2 3 0 IIIB LLL 70 35 2 47
105 3 1 0 IIIA LLL 70 35 2 33
106 0 2 0 IIIA mediastinum 66 33 2 143
107 2 2 0 IIIA LUL 63 35 1.8 18
108 2 2 0 IIIA RUL 70.2 39 1.8 12
109 4 2 0 IIIB RLL 59.4 33 1.8 392
110 2 3 0 IIIB RLL 62 31 2 55
111 3 1 0 IIIA RLL 64 32 2 75
112 3 2 0 IIIA RUL 63 35 1.8 31
113 1 1 0 IIA LLL 66 33 2 78
114 2 2 0 IIIA RLL 66 33 2 179
115 1 3 0 IIIB RUL 66.6 37 1.8 7
116 3 2 0 IIIA LUL 70 35 2 33
117 3 2 0 IIIA RUL 66 33 2 10
118 3 2 0 IIIA RUL 66 33 2 13
119 4 3 0 IIIB RUL 66 33 2 142
20
TABLE III. Planning 4DCT information for each subject.
Subject Planning 4DCT Is planning CT? acquisition time to Comments
study identier treatment start time (days)
100 S300 Y 14
101 S300 Y 9
102 S300 Y 18
103 S301 Y 13
104 S300 Y 15
105 S300 Y 13
106 S301 Y 18
107 S300 N -2 15 days after simulation
108 S304 N 0 12 days after simulation
109 S302 Y 12
110 S300 Y 14
111 S301 Y 12
112 S301 Y 26
113 S300 N -16 30 days after simulation
114 S300 N 0 12 days after simulation
115 S300 Y 13
116 S301 Y 14
117 S300 Y 10
118 S306 Y 12
119 S300 Y 14
`Is planning CT?' denotes if this image was used as the clinical planning CT. Acquisition
time to treatment start time gives the number of days from acquisition of this image to the
start of treatment (rst fraction). See also supplemental material17 for timing information.
21
TABLE IV. Hounseld unit to relative electron density calibration curve for the 4DCT images in
this study.
CT intensity (HU) electron density relative to water
-1000 0.00
-705 0.30
-569 0.41
-95 0.92
-42 0.98
0 1.00
40 1.05
86 1.11
225 1.14
227 1.16
473 1.34
845 1.56
1283 1.82
5812 5.76
9035 8.00
9754 8.50
22


